Integrated care — bringing together evidence-based medicine, innovation, and complementary approaches to help people live longer, healthier, and better.
Dutch 'dementia village' that offers beer, bingo, and top-notch healthcare
Get link
Facebook
X
Pinterest
Email
Other Apps
-
Residents of Hogeweyk, a village located in Weesp, Netherlands, lead a normal life. They go to the grocery store, complain about the weather, and enjoy a weekly game of bingo.
But there's one thing that sets the 152 residents apart from the general public: Everyone has an advanced form of dementia.
Hogeweyk is a nursing home disguised to look like the outside world. It helps people with mild to severe dementia suffer a little bit less in their remaining years, facility manager Eloy van Hal told Business Insider. He said it preserves people's sense of autonomy.
The village is comprised of 23 houses, each with six to seven residents and a caregiver who cooks, takes people to social events, helps them go grocery shopping at the village market, and watches over them to ensure their safety.
Here's what life is like inside Hogeweyk's walls.
Hogeweyk started in 1993 as your typical hospital-style nursing home. But the staff soon realized there was a better, more humane, way to offer care.
Hogewey
"We said to each other 'What do we want for ourselves and our moms and dads?" van Hal said.
The consensus was that people wanted normalcy, at least to the extent caregivers could provide it. Gradually, Hogeweyk began folding in elements of the outside world. It started by creating 23 houses in four different "lifestyle" categories — cosmopolitan, nature-oriented, well-to-do, and traditional Dutch.
"You have to choose," van Hal said. "Which is the lifestyle according to your preferences?"
Staff at Hogeweyk are trained to focus on highlighting what residents can do, not what they can't.
Hogewey
Hogeweyk places a great deal of importance on word choice, van Hal said. The staff members don't treat patients — they care for residents.
"All the residents living here need medical treatment, yes. They all have medication. They all have [an] advanced stage of dementia," van Hal said. "But they are first a person. That's why there are people living here with dementia, and not demented people."
Hogeweyk caregivers and house attendants use an in-house currency to help their residents buy groceries at a fully-functional supermarket.
Hogewey
The residents can also use real money if they want to, Hal said. Only a handful are lucid enough to do so, and typically they spend it on small items like toothpaste and candy bars.
As part of the facility's normal budgeting process, a chunk of money (not real currency) is doled out to each of the 23 houses. With some help from the caregivers, it's up to the houses to budget the money how they see fit over the course of the month.
"For us it's important that we support them to experience a normal day, a day they like and a day they recognize," van Hal said.
Hogewey
As a matter of policy, Hogeweyk rejects the idea that people with dementia ought to miss out on the finer things, such as beer or wine — even if they don't follow the social norms that most other people do.
"They have really bad manners and habits, in food and behavior," he said. "We are not going to change that."
Residents can use real money at the facility's pub. If people display signs of alcohol abuse, however, the facility will not serve them.
The staff of medical professionals tries to cater to each resident based on their unique needs, van Hal said.
Hogewey
That's important for a sensitive disease like dementia, he added. There are roughly 50 million people worldwide living with dementia, which means there are an equivalent number of stages at which the disease has advanced.
It's up to the Hogeweyk staff to know which residents are more lucid than others, and to treat them accordingly if they slip up with a name or date. According to van Hal, there is no single policy for bringing residents back into "the real world" or letting them live in their bubble.
Although certain homes are designed to accommodate introverts, there are a variety of social events available to residents, van Hal said. There are also bingo nights, social clubs, theater events, and plenty of chances to bump into neighbors.
Hogewey
Research has found that loneliness is just as deadly as smoking and twice as lethal as obesity. As seniors tend to be the age group that most often lives by themselves, Hogeweyk feels a responsibility to make sure people get as much social interaction as they require.
"You are busy, you are outside, you can complain about the weather," he said.
It's also important for residents to go outside, research has found. Hogewey tries to encourage residents to take walks or enjoy one of the several gardens.
Hogewey
Alzheimer's and dementia sufferers are widely encouraged to stay physically active to keep their minds and bodies engaged.
Residents at Hogewey can stroll through the open courtyard or help caregivers tend to one of the many gardens. Even just sitting on a bench in the outdoors can help improve their mood and overall well-being, research has found.
The efforts may only yield benefits for a few years. But van Hal said the small details can mean the most, even if it's just pouring a resident the perfect cup of coffee.
Hogewey
"If we know that you have sugar in your coffee, we will still ask you every day, 'Do you want sugar in your coffee?' so you can make that choice every day," van Hal said. "That you can still decide what you put in your coffee is important."
Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: November 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of November 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side e...
Medically Reviewed by: Dr Frank Yap, MD | Written and Compiled by: OneDayMD Editorial Team | Last Updated: October 2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork ...
GLP-1-based medications have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as these medicines become more widely used, another question has become increasingly important: How much of the weight lost on a GLP-1 drug comes from muscle or other lean tissue—and can that loss be minimized? The evidence shows a nuanced answer. People taking semaglutide, tirzepatide and related incretin-based medicines generally lose much more fat than lean tissue . At the same time, absolute lean mass usually falls during substantial weight loss. Importantly, lean mass is not the same thing as skeletal muscle : DXA-based “lean mass” also includes water, organs and other non-fat tissues. Therefore, a finding that lean mass decreased does not automatically mean that the same amount of skeletal muscle was lost. Recent 2026 meta-analyses suggest that roughly one-quarter to one-third of total weight lost with incretin therapy may be classified as lean ...
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: October 2026 If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories (800+ case reports) and a 2026 publication, " Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients : Results from a Prospective Observational Cohort of 197 patients." We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a sci...
Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 2026 Quick Answer Semaglutide (“sema”), tirzepatide (“tirz”), and retatrutide (“reta”) represent three stages in the evolution of incretin-based weight-loss medications: a single GLP-1 receptor agonist, a dual GIP/GLP-1 receptor agonist, and an investigational triple GIP/GLP-1/glucagon receptor agonist, respectively. Semaglutide is an FDA-approved GLP-1 receptor agonist that has demonstrated average weight loss of approximately 15% in clinical trials, with some individuals losing more. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated average weight loss of up to approximately 21–22% in trials. Retatrutide, an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, has shown promising weight-loss results in clinical trials but is not yet FDA-approved. What changed in this update (Oct 2026): replaced pre-Phase-3 esti...
Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: October 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks to ...
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem C...
Compiled and Curated by OneDayMD Editorial Team / Medically Reviewed by: Dr Frank Yap, MD | Last Updated: November 2026 Table of Contents: Editor's Preface Introduction Fenbendazole, Ivermectin and Mebendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories (133 cases) Brain Cancer (including Glioblastoma) (136 cases) Bladder Cancer Success Stories (including kidney cancer) (38 cases) Cervical Cancer (6 cases) Colorectal Cancer (including Appendix cancer) (91 cases) Esophageal and Stomach cancer (23 cases) Endometrial (Uterine) Cancer (17 cases) Gastric (Stomach) cancer (see Esophageal and Stomach Cancer ) Head and Neck Cancer (17 cases) Kidney Cancer Case Series (including urinary (urothelial) bladder cancer) Liver and Bile Duct Cancer (Hepato-biliary system) (10 cases) Lung Cancer (65...
Quick Summary: DMSO (Dimethyl Sulfoxide) is a naturally occurring compound with decades of research behind its use as an anti-inflammatory, analgesic, and cellular-protective agent. FDA-approved for interstitial cystitis, it has been used off-label by athletes, physicians, and patients for musculoskeletal injuries, chronic pain, wound healing, and more. This guide covers what DMSO is, how it works, the evidence for its key uses, safety considerations, dosing guidance, and where to find practitioners who use it. All off-label uses are experimental. Consult a qualified healthcare provider before use. A Patient Story: From Lung Transplant List to Clear CT Scans In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I d...
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 An updated, evidence-based guide to ivermectin's federal and state legal status, how to obtain a prescription, which states allow pharmacist-dispensed or OTC access, and a directory of pharmacies that fill ivermectin prescriptions in the US. Quick Answer (AI & Search Summary) Ivermectin is still classified federally as a prescription-only drug for human use. It has not been reclassified as OTC by the FDA. However, five states — Arkansas, Idaho, Louisiana, Tennessee, and Texas — have passed laws letting pharmacists dispense it without a doctor's prescription, and roughly half a dozen more have active bills. Everywhere else, you need a prescription from a doctor, urgent care provider, or telehealth service. Individual pharmacists retain the right to decline to dispense or stock it even where state law allows it. Table of Contents Current Legal Status (Federal & State) State-by-...
Comments
Post a Comment